Abstract Colorectal cancer (CRC) is one of the most prevalent cancers worldwide and a major cause of human morbidity and mortality. In addition to early detection, close monitoring of disease progression in CRC can be critical for patient prognosis and treatment decisions. Efforts have been made to develop new methods for improved early detection and patient monitoring; however, research focused on CRC surveillance for treatment response and disease recurrence using metabolomics has yet to be reported. In this proof of concept study, we applied a targeted liquid chromatography tandem mass spectrometry (LC-MS/MS) metabolic profiling approach focused on sequential metabolite ratio analysis of serial serum samples to monitor disease progression from 20 CRC patients. The use of serial samples reduces patient to patient metabolic variability. A partial least squares-discriminant analysis (PLS-DA) model using a panel of five metabolites (succinate, N2, N2-dimethylguanosine, adenine, citraconic acid, and 1-methylguanosine) was established, and excellent model performance (sensitivity=0.83, specificity=0.94, area under the receiver operator characteristic curve (AUROC)=0.91 was obtained, which is superior to the traditional CRC monitoring marker carcinoembryonic antigen (sensitivity=0.75, specificity=0.76, AUROC=0.80). Monte Carlo cross validation was applied, and the robustness of our model was clearly observed by the separation of true classification models from the random permutation models. Our results suggest the potential utility of metabolic profiling for CRC disease monitoring.
Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer death for both men and women. The American Cancer Society estimates that 132,700 people will be diagnosed in 2015 with colorectal cancer and 49,700 people will die of the disease in the USA [1] . Although the percentage of deaths due to CRC has steadily decreased over the years, the number of deaths is still unnecessarily high. Mass spectrometry (MS)-based metabolomics has also been shown recently to be a promising tool for analyzing metabolic alterations due to CRC, and can provide valuable information for diagnostics, pathogenesis clarification, and therapeutic targets for clinical treatments [2] . While these results are promising for CRC Electronic supplementary material The online version of this article (doi:10.1007/s00216-015-8984-8) contains supplementary material, which is available to authorized users.
screening and prevention, research focused on CRC disease status surveillance has been less often reported. CRC patient mortality is primarily caused by aggressive metastatic disease progression, rather than the primary tumor [3] . Therefore, after primary surgery/initial treatments, CRC patients are usually monitored using blood tests and/or imaging to ensure that they remain disease free and are treated promptly with medical or surgical therapies upon relapse. Additionally, malignant disease progression is ultimately associated with drug resistance; therefore, monitoring disease progression can indicate therapeutic response and/or suggest the need for alternative therapies. In general, a monitoring test needs to be both sensitive and specific to ensure either initiation/continuation of beneficial therapies or discontinuation/replacement of ineffective treatments.
The most widely used CRC monitoring test is the carcinoembryonic antigen (CEA); CEA is a glycoprotein involved in cell adhesion that is normally produced during fetal development. Production of this protein ceases prior to birth and is, therefore, not typically present in the blood of healthy adults [4] . Elevated levels of CEA (>2.5 ng/mL) are most commonly used as a biomarker for monitoring for relapse after CRC primary tumor resection, and for monitoring the response of metastatic CRC to systemic therapy. Ratio methods that compare sequential CEA measurements are also used, often with improved performance [5] . While CEA is FDA approved for these applications, elevated CEA levels are also associated with other types of carcinomas, such as gastric, pancreatic, lung, and breast, as well as nonmalignant diseases like bronchitis, pneumonia, and hypothyroidism, making it an unreliable biomarker solely for CRC cancer diagnosis or early cancer detection [6] . CEA levels correlate to recurrent CRC with a sensitivity of ∼80 % (range, 17-89 %) and specificity of ∼70 % (range, 34-91 %) [4, 7] , which is less than optimal.
In this study, we propose to monitor cancer progression by utilizing a targeted liquid chromatography tandem mass spectrometry (LC-MS/MS) approach to profile serum metabolites. Sequential metabolite ratio analysis of the serially acquired patient samples was used to identify metabolites that correlate with CRC patient disease status and reduce patient to patient variability. Individually, a number of metabolites showed a significant difference (p values <0.05) in their sequential ratios between CRC patients with progressing disease and CRC patients with other disease statuses (includes non-progressing CRC patients in remission/stable disease while on treatment, or with no evidence of disease after resection). The individual performance of several of these metabolites was higher than for CEA alone. Partial least squares-discriminant analysis (PLS-DA) was performed using sequential patient sample ratios of these metabolite biomarkers, and high sensitivity and specificity were obtained for the differentiation of CRC patients with disease progression status compared to patients with stable disease or complete remission. The results show promise for the use of the metabolite profile to monitor the CRC patient population.
Materials and methods
Clinical samples Patient recruitment and sample collection protocols were approved by institutional review boards at Purdue University and the Indiana University School of Medicine. Written informed consent was provided by all subjects in the study according to institutional guidelines. Longitudinal serum samples (49) were obtained from 20 CRC patients who participated in the Cancer Care Engineering project. A summary of patient information is shown in Table S2 in the Electronic Supplementary Material (ESM). The four major CRC disease statuses are defined as follows: at diagnosis (AD)-the patient has just been diagnosed with cancer and has not yet received any form of treatment for it; disease progression (DP)-the patient has a growing tumor (determined either clinically or by imaging), and the patient is usually on treatment but can also be off treatment; stable disease (SD)-the patient has a tumor and may or may not be on treatment, and imaging studies/clinical exam suggest that his/her tumor is the same size as determined in previous visits; and complete remission (CR)-the patient had a tumor and may or may not be on treatment, and imaging studies/clinical exam suggest that he/she has no visible tumor anymore. All samples were evaluated for serum CEA values at the time of collection, and this information was also utilized for comparison in this study. Each blood sample was allowed to clot for 45 min and then centrifuged at 1500g for 10 min. Serum aliquots were then stored at −80°C until experiments were performed.
Chemicals, sample preparation, and LC-MS/MS conditions
Chemicals and methods related to serum sample preparation and the targeted LC-MS/MS platform used for analysis were similar to those utilized in our previous report [8] , and are detailed in the ESM. All chemicals used in this study are LC-MS grade or above. Frozen samples were first thawed and then cold-methanol extraction of metabolites was performed. Chromatographic separations were performed on an Agilent 1260 HPLC system installed with two hydrophilic interaction chromatography (HILIC) columns. Targeted mass spectrometry was performed in multiple-reaction-monitoring (MRM) mode using an AB Sciex QTrap 5500 instrument.
Data analysis, model development, and cross validation
The extracted MRM peaks were integrated, and the spectral data were exported using MultiQuant 2.1 software (AB Sciex). Sequential metabolite ratios (i.e., the ratio of the metabolite from one blood draw to that from the previous blood draw of the same patient) were calculated before applying other further analyses. The calculated ratio values were linked to the disease status at the time of the more recent blood draw, so it is possible to see the ratios from the same patient belong to two different disease status groups (such as a patient initially diagnosed as DP but who later transformed to SD status). As an example, four blood samples were collected from patient no. 1 (Table S2) ; three ratio values can be obtained for every detectable metabolite in this study (blood draw 2/blood draw 1, 3/2, and 4/3). Three disease statuses from blood draw 2, 3, and 4 (SD, DP, and DP) were used to correspond to these three ratio values. There were only three groups of disease status (CR, DP, and SD) remaining after the ratio calculation.
Both univariate and multivariate statistical analyses were applied for metabolite biomarker discovery and model development on a selected set of biomarker candidates. MannWhitney U tests, generation of receiver operator characteristic (ROC) curves, and calculation of sensitivity, specificity, false discovery rate (FDR) and area under ROC curves (AUROCs) were performed using JMP Pro10 (SAS Institute). Partial least squares-discriminant analysis (PLS-DA) and Monte Carlo cross validation (MCCV, developed using in-house scripts) were performed using Matlab software (Mathworks, Natick, MA) installed with the PLS toolbox (Eigenvector Research Inc., Wenatchee, WA). MCCV was applied with 100 iterations, using 70 % of the data (randomly selected) as the training set while the remaining 30 % served as the testing set for each iteration. Three specificities, 0.95, 0.85, and 0.75, for the training sets were used to determine the thresholds of PLS-DA-predicted Y values. The same thresholds were then applied to the test set to determine sensitivities and specificities. The sample classification can be correctly assigned, termed Btrue class,^or the sample class information can be randomly permuted, which is referred to as Brandom permutation.^Pathway enrichment and topology analysis were performed using the on-line server MetaboAnalyst 3.0 (http://www.metaboanalyst.ca/ MetaboAnalyst/faces/home.xhtml) [9] .
Results and discussion
The targeted platform and HILIC chromatography-MS/MS method used in this study could detect 162 metabolites (see Table S1 ), representing more than 20 different classes (such as amino acids, carboxylic acids, pyridines, etc.) from 25 important metabolic pathways (e.g., TCA cycle, amino acid metabolism, purine and pyrimidine metabolism, glycolysis, etc.). In this study, 131 metabolites were reproducibly detected in the 49 samples, with an average coefficient of variation (CV) of 7.1 %.
CEA values were available for all 49 samples and the AUROC was calculated as 0.77. The sensitivity and specificity were 0.86 and 0.44, respectively, for the typical cutoff value of 2.5 ng/mL. At 5 ng/mL, the sensitivity and specificity were 0.86 and 0.67, respectively. Often, DP is better identified in CRC patients using CEA ratios calculated from sequential samples [5, 10] , and therefore, we also evaluated the CEA performance for CRC DP monitoring based on its ratio of serial blood draws from the same patient, although with 29 ratios for the 20 patients, we did not have sufficient samples to calculate exponentially fitted slopes [10] . Using a ratio cutoff value of 1.2, the sensitivity and specificity are 0.75 and 0.76, respectively (lower cutoff values can be used, which would increase the detection sensitivity but also decrease the specificity). The AUROC was 0.80 for the differentiation of DP from both complete remission and stable disease (CR+ SD) groups (Fig. 1a) .
Metabolite data were then analyzed after calculating the sequential metabolite ratios for serial patient samples. Both univariate and multivariate statistical methods were used for metabolite biomarker selection. After applying the univariate Mann-Whitney U test, 19 metabolites from different compound classes, such as monosaccharides, amino acids, carboxylic acids, and nucleosides, showed a significant statistical difference (p<0.05) between CRC DP and CR+SD. The pvalues, fold changes, and false discovery rate (FDR) for these metabolites are listed in Table 1 . Furthermore, highly significant changes (defined as p<0.01) between CRC DP and CR+ SD were found for six metabolites, namely succinate, N2, N2-dimethylguanosine, adenine, citraconic acid, methylmalonate, and 1-methylguanosine. We established the individual ROCs for each of these six metabolites for monitoring the CRC disease progression (see ESM Fig. S1 ). Some of these metabolites had good AUROCs, such as 0.83 for succinate and 0.82 for N2, N2 dimethylguanosine, which represents better performance than CEA (or its sequential sample ratio) alone.
Furthermore, PLS-DA was utilized to identify the performance of multiple metabolite biomarkers in combination for monitoring CRC DP. Variable importance in projection (VIP) scores from the PLS-DA of all metabolites was calculated to evaluate those metabolites that contributed most to the differentiation of CRC DP from CR and SD (see ESM Table S3 for metabolites with VIP>1.5). A series of PLS-DA models was then established based on the different VIP thresholds (from 1.5 to 2); the model performances were evaluated and are listed in ESM Table S4 . Interestingly, when the VIP threshold was set to 2, five out of the six metabolites (succinate, N2, N2-dimethylguanosine, adenine, citraconic acid, and 1-methylguanosine) that had p<0.01 were again selected as important biomarkers for CRC DP monitoring.
A PLS-DA model using only these five core metabolite biomarkers was then applied to evaluate the performance of this approach for CRC DP monitoring, and the ROC curve generated for this metabolite model is shown in Fig. 1b . This five-metabolite model demonstrated excellent performance with an AUROC of 0.91, a sensitivity of 0.83, a specificity of 0.94, and a FDR of 0.09. To further test the robustness of this model, MCCV was applied with three different specificities. The true classification models clearly outperformed the random permutation models (Fig. 1c) , suggesting that the five core metabolite biomarker model is reliable for the CRC DP monitoring. Adding the CEA ratio to the five-metabolite model slightly improved performance (AUROC increased from 0.907 to 0.912, ESM Fig. S2 ), again with a FDR of 0.09. While these results are promising, further studies are needed to determine whether the combination of both metabolite biomarkers and CEA provides the most robust utility for the close monitoring of patients for CRC DP. In order to evaluate model overfitting, an additional permutation test was performed [11] . After randomizing the sample labels, individual metabolite performance was first calculated, and no metabolite showing significant disease monitoring ability was observed when tested with a null data set. Using random labels, the results showed an average AUROC <0.53 and a standard deviation <0.13 for 100 runs. Furthermore, the same variable selection and model setup procedure was performed 100 times. The null data sets resulted in an average AUROC of 0.76 with a standard deviation of 0.04, indicating some overfitting that may be due to the limitation of a small sample size. Nevertheless, this result is still significantly lower than our actual model performance of 0.91.
A further refined analysis using a subset of our samples from stage IV patients was also conducted, as these patients are the most likely to experience disease progression. A comparison of Table S5 . Interestingly, the five core metabolite biomarkers were among the metabolites in this list. A PLS-DA model using only stage IV patient sequential metabolite ratios of these five metabolites and CEA also showed a good performance (ESM Fig. S3 ) with an AUROC=0.84, a sensitivity of 0.91, a specificity of 0.82, and a FDR of 0.17. This result again suggests the potential usefulness of this targeted metabolite profiling approach for CRC DP monitoring, especially for stage IV patients who experience a high risk for disease progression.
Significantly changed metabolites discovered in this study are involved in multiple important metabolic pathways, such as the tricarboxylic acid (TCA) cycle, glycolysis, amino acid metabolism, purine metabolism, the urea cycle, and their related pathways. In order to investigate the perturbation of CRC progression to multiple metabolic pathways in this study, pathway enrichment and pathway topology analysis were performed on the data using MetaboAnalyst [9] , and a metabolome view is shown in ESM Fig. S4 . Meanwhile, efforts were made to understand the possible connections among these serum metabolite perturbations. A metabolic pathway map showing significantly changed metabolites was also constructed (see Fig. 2 ) using reference information obtained from the Kyoto Encyclopedia of Genes and Genomes website (www.genome.jp/kegg/). Six significantly altered metabolites in this study, namely galactose, pyruvate, cystathionine, 3 nitro-tyrosine, ornithine, and methyl succinate, showed decreased levels in CRC DP serum samples in comparison with CR and SD. On the other hand, 13 significantly altered metabolites, including glucose 1, 6-bisphosphate (G16BP); fructose 1, 6-bisphosphate (F16BP); 1-methylguanosine; 2-aminoadipate; citraconic acid; N2, N2-dimethylguanosine; oxaloacetate; cis-aconitate; succinate; homogentisate; methylmalonate; adenine; and urate, increased in the CRC DP group. Several of the biological discoveries in this study are consistent with previously published results. For example, G16BP and F16BP showed a significant increase in our CRC cancer-progressing patients. Similarly, a recent Fig. 2 Metabolic network of significantly changed metabolites in several important pathways (e.g., glycolysis, TCA, purine and pyrimidine metabolism). Bar chart: blue horizontal lines (left), disease progression (DP); red upward diagonal lines (right), complete remission and stable disease (CR+SD). Dashed arrows indicate multiple steps involved in pathway connections, which were simplified due to space restrictions. Y-axis represents the metabolite level ratios: *p<0.05; **p<0.01 gastric cancer study suggested that fructose-1, 6-bisphosphatase-2 (FBP2), the enzyme that catalyzes the hydrolysis of F16BP to fructose-6-phosphate and inorganic phosphate in glucose metabolism, was downregulated in gastric cancer patient tissue [12] , which could lead to the accumulation of upstream F16BP. Pyruvate, the major downstream product of glycolysis, was significantly lower in CRC DP patients compared to CR and SD in this study, which matches the observations from several other studies [13, 14] . Proposed mechanisms behind this observation are that CRC cells try to (1) maintain low levels of pyruvate to avoid cell death caused by histone deacetylases (HDAC) [14] and (2) also overexpress pyruvate dehydrogenase kinase to increase drug resistance and early recurrence [13] . Increased levels of modified nucleosides, such as N2, N2-dimethylguanine, have been observed in urine from patients suffering from CRC [15, 16] , which is also in agreement with the current study. Increased levels of three TCA cycle metabolites (succinate, oxaloacetate, and cis-aconitate) were observed in this study, which may suggest a typical metabolic fingerprint of mitochondrial dysfunction in hypoxic cells [17] ; however, it is uncertain what causes the accumulation of these metabolites in CRC DP samples. While the results shown in this study are promising, other confounding factors such as the patient response to therapeutic treatments can also be the cause of certain metabolite variations, which were not controlled in the experimental design due to its complexity in this group of patients, and was therefore not within the scope of this study.
Conclusions
To the best of our knowledge, this is the first study in which an LC-MS/MS targeted serum metabolic profiling approach combined with sequential metabolite ratio analysis has been applied to distinguish CRC disease progression patients from CRC patients with complete remission and stable disease. Our results demonstrate that a panel of five core serum metabolites (succinate, N2, N2-dimethylguanosine, adenine, citraconic acid, and 1-methylguanosine) can be used for sensitive and specific CRC disease status monitoring. Furthermore, with the enhancement provided by adding CEA to the model, this metabolic profiling approach and sequential ratio analysis can potentially serve as a novel tool for CRC disease status monitoring and provide useful information for many CRC-related healthcare decisions. While these findings from a small sample size are promising, further studies with larger patient cohorts will be needed to substantiate the results, verify the important biological roles of these key metabolites, and determine any association of the derived metabolite markers with pathologically different CRC disease status. Considering their strong performance as biomarkers in the present study, these five core metabolites as well as larger profiles might be of particular interest for further validation studies.
